FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit
Kelly J Norsworthy1, Rosa J Lee-Alonzo2, Richard Pazdur2
1Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. kelly.norsworthy@fda.hhs.gov.
Nature Reviews. Clinical Oncology
|February 21, 2024
Abstract
No abstract available in PubMed .


